Page 339 - Read Online

Page 16 of 17 Shrestha et al. Hepatoma Res 2019;5:32 I http://dx.doi.org/10.20517/2394-5079.2019.24

Science 2018;360:858.
76. Sul J, Blumenthal GM, Jiang X, He K, Keegan P, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With
Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. Oncologist 2016;21:643-50.
77. Ma K, Jin Q, Wang M, Li X, Zhang Y. Research progress and clinical application of predictive biomarker for immune checkpoint
inhibitors. Expert Rev Mol Diagn 2019;19:517-29.
78. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
79. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelial-mesenchymal transitions: the importance of changing
cell state in development and disease. J Clin Invest 2009;119:1438-49.
80. Rao SR, Jayachandran A. Epithelial-to-mesenchymal transition as a potential target for antineoplastic therapies. J Cancer Clin Trials
2016;1:e103.
81. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
82. Jayachandran A, Shrestha R, Dhungel B, Huang IT, Vasconcelos MYK, et al. Murine hepatocellular carcinoma derived stem cells
reveal epithelial-to-mesenchymal plasticity. World J Stem Cells 2017;9:159-68.
83. Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal 2014;7:re8.
84. Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular
carcinoma. J Hematol Oncol 2016;9:74.
85. Singh M, Yelle N, Venugopal C, Singh SK. EMT: Mechanisms and therapeutic implications. Pharmacol Ther 2018;182:80-94.
86. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-
induced EMT of cancer cells. Cancer Cell 2009;15:195-206.
87. Giannelli G, Koudelkova P, Dituri F, Mikulits W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol
2016;65:798-808.
88. Bertran E, Caja L, Navarro E, Sancho P, Mainez J, et al. Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells
that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta. Cell Signal 2009;21:1595-
606.
89. Bertran E, Crosas-Molist E, Sancho P, Caja L, Lopez-Luque J, et al. Overactivation of the TGF-β pathway confers a mesenchymal-like
phenotype and CXCR4-dependent migratory properties to liver tumor cells. Hepatology 2013;58:2032-44.
90. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, et al. TGFbeta-mediated upregulation of hepatic miR-181b promotes
hepatocarcinogenesis by targeting TIMP3. Oncogene 2010;29:1787-97.
91. Wang MH, Sun R, Zhou XM, Zhang MY, Lu JB, et al. Epithelial cell adhesion molecule overexpression regulates epithelial-
mesenchymal transition, stemness and metastasis of nasopharyngeal carcinoma cells via the PTEN/AKT/mTOR pathway. Cell Death
Dis 2018;9:2.
92. Yamada S, Okumura N, Wei L, Fuchs BC, Fujii T, et al. Epithelial to mesenchymal transition is associated with shorter disease-free
survival in hepatocellular carcinoma. Ann Surg Oncol 2014;21:3882-90.
93. Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, et al. MUC1-C integrates PD-L1 induction with repression of immune effectors in
non-small-cell lung cancer. Oncogene 2017;36:4037-46.
94. Terry S, Savagner P, Ortiz-Cuaran S, Mahjoubi L, Saintigny P, et al. New insights into the role of EMT in tumor immune escape. Mol
Oncol 2017;11:824-46.
95. Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, et al. Targeting the Interplay between Epithelial-to-Mesenchymal-
Transition and the Immune System for Effective Immunotherapy. Cancers 2019;11:714.
96. Ye LY, Chen W, Bai XL, Xu XY, Zhang Q, et al. Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma
Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis. Cancer Res 2016;76:818-30.
97. Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, et al. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular
Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res 2016;22:609-20.
98. Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, et al. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor
Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin
Cancer Res 2016;22:3630-42.
99. Kim S, Koh J, Kim MY, Kwon D, Go H, et al. PD-L1 expression is associated with epithelial-to-mesenchymal transition in
adenocarcinoma of the lung. Hum Pathol 2016;58:7-14.
100. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of
tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014;5:5241.
101. David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, et al. A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein
(M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology 2017;6:e1349589.
102. Chae YK, Chang S, Ko T, Anker J, Agte S, et al. Epithelial-mesenchymal transition (EMT) signature is inversely associated with
T-cell infiltration in non-small cell lung cancer (NSCLC). Sci Rep 2018;8:2918.
103. Hirai M, Kitahara H, Kobayashi Y, Kato K, Bou-Gharios G, et al. Regulation of PD-L1 expression in a high-grade invasive human
oral squamous cell carcinoma microenvironment. Int J Oncol 2017;50:41-8.
104. Noman MZ, Janji B, Abdou A, Hasmim M, Terry S, et al. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated
human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology 2017;6:e1263412.
105. Chen L, Xiong Y, Li J, Zheng X, Zhou Q, et al. PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human
Esophageal Cancer. Cell Physiol Biochem 2017;42:2267-80.